Eli Lilly (LLY)

Groundbreaking ALS Therapy Shows Remarkable Survival Benefits as NeuroSense Continues to Advance Toward Potential Partnership with Pharma Giant (NASDAQ: NRSN)*

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".

Edwards Lifesciences stock was flat late Wednesday after the medtech company beat profit views and delivered in-line sales.

Bristol Myers' Cobenfy missed its primary endpoint in the Phase 3 ARISE trial but showed symptom improvement in certain subgroups.

The company unveiled three seventh-generation robotaxi models developed through its partnerships with Toyota, BAIC, and GAC at the Shanghai International Automobile Industry Exhibition on Wednesday.

According to a CNBC report, the company filed lawsuits against Mochi Health, Fella Health, Willow Health, and Henry Med on Wednesday, alleging that they deceived consumers about “untested, unapproved drugs.”

Boston Scientific stock jumped Wednesday after the medtech company beat first-quarter expectations and hiked its sales view.

Take a deep dive into Eli Lilly's latest clinical GLP-1 results that sent shares soaring. The company has a big opportunity to serve needle-phobic patients.

The Trump Administration is reportedly mulling over a policy to match U.S. drug prices with those in other developed nations.

The competitive landscape for GLP-1 agonist weight loss drugs has undergone a significant shake-up.

Today's Research Daily features a real-time scorecard of the Q1 earnings season and freshly updated research reports on 16 major stocks, including NVIDIA Corporation, Alphabet Inc., and Berkshire Hathaway Inc..

Intuitive Surgical stock plunged late Tuesday on worries about potential tariffs. The impact "could be material."

Roche to invest $50 billion in U.S. over five years, adding 12,000+ jobs and expanding manufacturing, R&D, and export capacity across eight states.

Eli Lilly gains analyst support after Phase 3 success. Bullish forecasts for obesity dominance and key earnings are set for May 1.

Reports suggest Novo Nordisk has asked the FDA to approve its oral semaglutide, two years after reporting a Phase 3 win.

The request reportedly came two years after a Phase 3 study of Rybelsus, an oral formulation of semaglutide, which showed successful results.